Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics Inc (NQ: PLRX )

14.02 +0.13 (+0.94%)
Streaming Delayed Price Updated: 2:47 PM EST, Nov 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 137,028
Open 14.04
Bid (Size) 13.99 (3)
Ask (Size) 14.04 (5)
Prev. Close 13.89
Today's Range 13.80 - 14.69
52wk Range 12.61 - 36.64
Shares Outstanding 35,937,937
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis
INTEGRIS-PSC interim results highlighted in an oral late-breaker presentation 
From Pliant Therapeutics, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Pliant Therapeutics
Via Benzinga

Performance

YTD
-26.21%
-26.21%
1 Month
+0.50%
+0.50%
3 Month
-16.10%
-16.10%
6 Month
-40.06%
-40.06%
1 Year
-28.18%
-28.18%

More News

Read More
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Where Pliant Therapeutics Stands With Analysts
Via Benzinga
Expert Ratings for Pliant Therapeutics
Via Benzinga
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Johnson Controls International To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Wednesday
Via Benzinga
Pliant Therapeutics Reveals Encouraging Data From Liver Disease Trial
Via Benzinga
Why TD SYNNEX Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Shares of Pliant Therapeutics Are Rising Tuesday
Via The Motley Fool
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis – Could GRI-0621 Be The Solution?
Via Benzinga
Pliant Therapeutics to Participate in Upcoming Investor Conferences
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
From Pliant Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.